The stock of Novabay Pharmaceuticals Inc (NBY) has seen a -9.60% decrease in the past week, with a -4.59% drop in the past month, and a -13.48% decrease in the past quarter. The volatility ratio for the week is 7.80%, and the volatility levels for the past 30 days are at 7.07% for NBY. The simple moving average for the last 20 days is -1.18% for NBY stock, with a simple moving average of -64.82% for the last 200 days.
Is It Worth Investing in Novabay Pharmaceuticals Inc (AMEX: NBY) Right Now?
The 36-month beta value for NBY is also noteworthy at 0.64. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NBY is 4.89M, and at present, short sellers hold a 0.78% of that float. The average trading volume of NBY on January 10, 2025 was 453.35K shares.
NBY) stock’s latest price update
The stock price of Novabay Pharmaceuticals Inc (AMEX: NBY) has plunged by -11.51 when compared to previous closing price of 0.64, but the company has seen a -9.60% decline in its stock price over the last five trading sessions. zacks.com reported 2024-12-25 that NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analysts’ Opinion of NBY
Many brokerage firms have already submitted their reports for NBY stocks, with Ladenburg Thalmann repeating the rating for NBY by listing it as a “Buy.” The predicted price for NBY in the upcoming period, according to Ladenburg Thalmann is $1.10 based on the research report published on September 18, 2019 of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NBY reach a price target of $4. The rating they have provided for NBY stocks is “Buy” according to the report published on July 06th, 2018.
Laidlaw gave a rating of “Buy” to NBY, setting the target price at $8 in the report published on November 15th of the previous year.
NBY Trading at -10.55% from the 50-Day Moving Average
After a stumble in the market that brought NBY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.78% of loss for the given period.
Volatility was left at 7.07%, however, over the last 30 days, the volatility rate increased by 7.80%, as shares sank -3.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.56% upper at present.
During the last 5 trading sessions, NBY fell by -8.80%, which changed the moving average for the period of 200-days by -87.37% in comparison to the 20-day moving average, which settled at $0.5720. In addition, Novabay Pharmaceuticals Inc saw -5.99% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NBY
Current profitability levels for the company are sitting at:
- -0.4 for the present operating margin
- 0.61 for the gross margin
The net margin for Novabay Pharmaceuticals Inc stands at -0.9. The total capital return value is set at -2.37. Equity return is now at value -246.52, with -119.49 for asset returns.
Based on Novabay Pharmaceuticals Inc (NBY), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -86.51. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -5.15.
Currently, EBITDA for the company is -4.8 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 0.27. The receivables turnover for the company is 15.91for trailing twelve months and the total asset turnover is 2.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.15.
Conclusion
In summary, Novabay Pharmaceuticals Inc (NBY) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
